During the last 3 months Ucb SA insiders have not bought any shares, and have not sold any shares. The stock price has increased by 17% over this period (open performance analysis).

The last transaction was made on Aug 1, 2021 by Lund- Jürgensen Kirsten , who bought 328.6k EUR worth of UCB shares.

Last Transactions:
Lund- Jürgensen Kirsten
€+328.6k
View All Transactions

During the last 3 months Ucb SA insiders have not bought any shares, and have not sold any shares. The stock price has increased by 17% over this period (open performance analysis).

The last transaction was made on Aug 1, 2021 by Lund- Jürgensen Kirsten , who bought 328.6k EUR worth of UCB shares.

Sold
0-3
months
0 EUR
0
3-6
months
0 EUR
0
6-9
months
0 EUR
0
9-12
months
0 EUR
0
Bought
0-3
months
No Insider Transactions
0
0 EUR
3-6
months
No Insider Transactions
0
0 EUR
6-9
months
No Insider Transactions
0
0 EUR
9-12
months
No Insider Transactions
0
0 EUR

Ucb SA
Insider Trading Chart

Ucb SA
Insiders Performance

1 Week Later 1 Month Later 3 Months Later 6 Months Later 1 Year Later
Average Return
Median Return
Win Rate

Ucb SA
Last Insider Transactions

Global
Insiders Monitor

Ucb SA
Glance View

Market Cap
46.3B EUR
Industry
Pharmaceuticals

UCB SA, a Belgian multinational biopharmaceutical company, stands at the forefront of innovation in the medical field, committed to creating value by discovering new ways to treat severe diseases. Founded in 1928, UCB has transformed over the decades from its initial focus in chemicals to pioneering developments in advanced therapeutics targeting central nervous system disorders and immunology. Anchored by a robust research pipeline and a keen focus on rare diseases and specialty care, UCB has established a strong presence globally, reflecting its strategic pivot toward patient-centric approaches. With primary research facilities stationed in Braine-l'Alleud, Belgium, and Slough, UK, the company's scientific endeavors are bolstered by collaborations with research institutions worldwide, fostering an environment ripe for breakthrough discoveries. Financially, UCB's revenue streams are predominantly derived from its established portfolio of blockbuster drugs, such as Cimzia, Vimpat, and Keppra, which serve as critical lifelines for patients dealing with autoimmune diseases, epilepsy, and other chronic conditions. The company thrives on a dynamic business model that combines in-house scientific research with strategic partnerships and acquisitions to enhance its competitive edge. This synergy not only facilitates sustained growth in its core markets but also drives expansion into emerging ones, underscoring its global reach. By reinvesting substantial portions of its earnings into research and development, UCB ensures a steady pipeline of new products, thereby maintaining its stature in the highly competitive biopharmaceutical landscape. Through such strategic maneuvers, UCB aligns its operations with the overarching goal of delivering transformative therapies that improve the quality of life for patients around the world.

UCB Intrinsic Value
238.26 EUR
Overvaluation 2%
Intrinsic Value
Price

What is Insider Trading?

Insider trading refers to the buying or selling of a company’s stock by individuals with access to non-public, material information about the company.

While legal insider trading occurs when insiders follow disclosure rules, illegal insider trading involves trading based on confidential information and is prohibited by law.

Why is Insider Trading Important?

It isn't a coincidence that corporate executives seem to always buy at the right times. After all, they have access to every bit of company information you could ever want.

However, the fact that company executives have unique insights doesn't mean that individual investors are always left in the dark. Insider trading data is out there for all who want to use it.

Peter Lynch

Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.

Back to Top